New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:59 EDTESRX, ZGNXZogenix price target lowered to $2.50 from $5 at Oppenheimer
Oppenheimer cut its price target on Zogenix (ZGNX) after coverage of the company's Zohydro painkiller was terminated by Express Scripts (ESRX). However, the firm thinks recent disappointing news about Zogenix is already reflected in the stock. Oppenheimer keeps an Outperform rating on the shares.
News For ZGNX;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
10:28 EDTESRXLeerink pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
10:01 EDTESRXOn the Fly: Analyst Initiation Summary
Subscribe for More Information
07:36 EDTESRXExpress Scripts initiated with an Equal Weight at Stephens
Subscribe for More Information
January 20, 2015
06:44 EDTESRXExpress Scripts downgraded to Neutral from Buy at UBS
Subscribe for More Information
January 13, 2015
12:17 EDTESRXExpress Scripts CEO says new cholesterol lowering drugs 'pretty expensive'
12:15 EDTESRXExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
12:10 EDTESRXExpress Scripts CEO says 'never stopped talking to Gilead'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use